Welcome to our dedicated page for STANDARD BIOTOOLS SEC filings (Ticker: LAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
When Standard BioTools Inc.鈥檚 mass cytometry systems shape immunotherapy studies worldwide, even a single line in the 10-K can move markets. Investors often ask, 鈥淲here can I review Standard BioTools quarterly earnings report 10-Q filing?鈥� or 鈥淗ow do I track Standard BioTools insider trading Form 4 transactions?鈥� Those answers live inside dense SEC documents鈥攆inding them can drain hours.
Stock Titan turns that complexity into clarity. Our AI delivers Standard BioTools SEC filings explained simply, spotlighting revenue from proteomics instruments, R&D cash burn, and obligations tied to leased manufacturing sites. You鈥檒l see each Standard BioTools annual report 10-K simplified and Standard BioTools 8-K material events explained within minutes of hitting EDGAR. AG真人官方-time alerts surface Standard BioTools Form 4 insider transactions real-time, ensuring you never miss meaningful Standard BioTools executive stock transactions Form 4. Need faster context? Every Standard BioTools earnings report filing analysis pairs key metrics with peer benchmarks for immediate comparison.
Whether you鈥檙e building a valuation model or evaluating management incentives, critical disclosures are one click away:
- Track Standard BioTools proxy statement executive compensation to understand leadership alignment
- Compare margins and backlog across each Standard BioTools quarterly earnings report 10-Q filing
- Receive alerts on emerging risks via Standard BioTools 8-K material events explained
Understanding Standard BioTools SEC documents with AI means spending less time scrolling and more time deciding. Every filing, every footnote鈥攄ecoded and delivered in real time.
Standard BioTools (NASDAQ:LAB) submitted a routine Form 4 disclosing director Troy Cox received 94,592 restricted stock units (RSUs) that vest in full by June 20 2026 and a stock option for 125,660 shares at an exercise price of $1.05, vesting in 12 equal monthly installments beginning July 20 2025.
Following these grants, Cox鈥檚 beneficial ownership stands at 256,412 common shares. No shares were sold, and the filing contains no additional transactions or financial disclosures.
Standard BioTools Inc. (LAB) has reported insider equity awards to Director Fenel M. Eloi on Form 4 dated 06/24/2025. On 06/20/2025 Eloi received 94,592 Restricted Stock Units (RSUs) valued at $0 per unit and 125,660 non-qualified stock options with an exercise price of $1.05 per share. The RSUs vest in full on the earlier of 20 June 2026 or one day before the next annual meeting, while the options vest in twelve equal monthly tranches beginning 20 July 2025 and expire 20 June 2035.
After these grants, Eloi鈥檚 direct holdings increase to 236,183 common shares and 125,660 options. The transaction code 鈥淎鈥� indicates the shares and options were awarded by the company rather than purchased on the open market. No Rule 10b5-1 trading plan was noted, and the filing concerns routine director compensation rather than open-market buying or selling.
Standard BioTools Inc. (LAB) 鈥� Form 4 insider transaction filed 06/24/2025
Director Thomas D. Carey reported two equity awards dated 06/20/2025:
- 94,592 Restricted Stock Units (RSUs) that vest in full on the earlier of 20 Jun 2026 or one day prior to the company鈥檚 next annual meeting, contingent on continued service. Each RSU converts into one share of common stock upon vesting.
- 188,490 stock options with a $1.05 exercise price, becoming exercisable in 12 equal monthly installments beginning 20 Jul 2025 and expiring 20 Jun 2035, also subject to continued service.
Following these grants, Carey鈥檚 direct beneficial ownership stands at 194,058 common shares. No dispositions were reported; the grants were acquired at $0 cost (for RSUs) and standard option pricing applies upon exercise. The filing does not reference any 10b5-1 trading plan.
The reported awards reflect routine director compensation and do not involve open-market purchases or sales; therefore, immediate dilution or cash impact to shareholders is negligible. Investors may view the transaction primarily as a governance disclosure rather than a signal of near-term fundamentals.
Standard BioTools Inc. (LAB) Form 4 filing dated 06/24/2025 details new equity awards granted to director and 鈮�10% shareholder Eli Casdin.
- Restricted Stock Units (RSUs): 94,592 RSUs awarded on 06/20/2025; they vest in full on the earlier of 06/20/2026 or one day prior to the next annual meeting, conditional on continued service. Each RSU converts into one common share.
- Stock Options: Option covering 125,660 shares with a $1.05 exercise price, granted 06/20/2025. The option vests in 12 equal monthly installments beginning 07/20/2025 and expires 06/20/2035.
- Post-transaction ownership: 2,901,062 shares held directly. Through affiliated investment funds, Casdin controls an additional 76,075,636 shares (13,939,637 via Casdin Private Growth Equity Fund II, 2,744,219 via Casdin Private Growth Equity Fund, and 59,391,780 via Casdin Partners Master Fund).
- Role: Casdin is both a director and 鈮�10% beneficial owner, indicating significant ongoing influence.
No purchase or sale of shares occurred; the awards were granted at no cost, reflecting routine director compensation and aligning incentives with shareholders. The filing does not disclose any earnings data, cash consideration, or changes to company guidance.
Standard BioTools (NASDAQ:LAB) filed a Form 4 disclosing equity awards to director Kathy L. Hibbs executed on 20 Jun 2025.
The filing reports the grant of 94,592 restricted stock units (RSUs) that vest in full on 20 Jun 2026 or one day before the next annual shareholders鈥� meeting, contingent on continued service. Following the award, Hibbs鈥� direct ownership increased to 137,720 common shares.
In addition, Hibbs received a stock option for 125,660 shares exercisable at $1.05 per share. The option vests in twelve equal monthly instalments starting 20 Jul 2025 and expires 20 Jun 2035.
No shares were sold; all reported transactions were acquisitions recorded under direct ownership. The activity appears to reflect routine director compensation rather than open-market buying.
Form 4 filing for Standard BioTools Inc. (LAB) dated 24 June 2025 discloses equity compensation granted to board member Frank Witney on 20 June 2025.
Restricted Stock Units (RSUs): Witney received 94,592 RSUs at no cost. The award vests in full on the earlier of 20 June 2026 or one day prior to the company鈥檚 next annual shareholder meeting, contingent on continued service. Each RSU converts into one share of common stock upon vesting. After the grant, the director鈥檚 direct holdings rise to 210,862 shares; an additional 4,225 shares are held indirectly through a family trust.
Stock Option: He also received a non-qualified option for 125,660 shares with a strike price of $1.05. The option vests in twelve equal monthly installments starting 20 July 2025 and expires 20 June 2035. The filing reports no disposals and no cash paid for the RSUs; any cash impact would occur only if the option is exercised.
The transaction reflects a routine, service-based compensation grant rather than an open-market purchase, aligning director incentives with shareholder value but producing no immediate effect on cash flow or operations. If fully vested and exercised, the awards could increase the company鈥檚 outstanding share count by up to 220,252 shares, but the filing provides no data to assess relative dilution.
JPMorgan Chase Financial Company LLC, fully guaranteed by JPMorgan Chase & Co., plans to issue Market-Linked Securities that combine a contingent fixed return with partial downside protection linked to the S&P 500 Index. The two-year notes will price on 26 Jun 2025, settle on 1 Jul 2025, and mature on 1 Jul 2027.
Key payout mechanics:
- Principal: $1,000 per security.
- Contingent fixed return: at least 11.40% ($114) if the Index closes on the calculation day at or above the threshold level (85% of the starting level).
- Buffer: 15% downside protection; below the threshold investors participate 1-for-1 in losses, risking up to 85% of principal.
- Estimated value at pricing: ~$961.10 (final value not lower than $940), highlighting an initial fair-value discount versus the $1,000 issue price.
Distribution economics: Wells Fargo Securities may receive up to 2.575% in selling concessions, with dealers including Wells Fargo Advisors retaining 2.00% and an additional 0.075% distribution fee; JPMS may pay up to 0.20% to selected dealers.
Risk highlights include potential loss of up to 85% of principal, limited upside to the fixed return, credit exposure to both JPMorgan Financial and JPMorgan Chase & Co., lack of secondary-market liquidity, and uncertain tax treatment. The securities are unsecured, non-interest-bearing, and not FDIC-insured.
Investors seeking enhanced yield relative to conventional notes may find the 11.40% contingent return attractive, but should weigh the credit risk, fee load, and asymmetric return profile versus a direct S&P 500 investment.
Standard BioTools Inc. (Nasdaq: LAB) filed an 8-K reporting the outcomes of its 2025 Annual Meeting held on 18 June 2025. Shareholder turnout was high, with 326,864,517 votes cast, representing approximately 86.06% of the 379,822,268 shares outstanding on the 25 April 2025 record date.
The meeting covered four key proposals, all of which passed with comfortable majorities:
- Election of two Class III directors: Kathy Hibbs (96.2% support) and Frank Witney, Ph.D. (97.9% support) were elected to serve until the 2028 annual meeting.
- Say-on-Pay: Executive compensation for FY 2024 received 97.0% shareholder approval (241.1 million FOR vs. 4.0 million AGAINST).
- Auditor ratification: PricewaterhouseCoopers LLP was re-appointed for FY 2025 with 98.8% support (322.9 million FOR).
- Equity Incentive Plan amendment: Shareholders approved increasing the Amended and Restated 2011 Equity Incentive Plan share reserve by 17.4 million shares (223.4 million FOR, 19.6 million AGAINST).
The additional share reserve expands the pool available for future equity grants to employees and directors. Full plan details are provided in Exhibit 10.1, with prior discussion in the company鈥檚 30 April 2025 proxy statement.
No other material transactions, financial results or leadership changes were disclosed in this filing.
FAQ
What is the current stock price of STANDARD BIOTOOLS (LAB)?
What is the market cap of STANDARD BIOTOOLS (LAB)?
What is the primary focus of Standard BioTools Inc.?
What technologies does Standard BioTools utilize?
How does Standard BioTools serve the research community?
What are the main business segments of Standard BioTools?
How does the company differentiate itself from competitors?
What kind of research applications benefit from Standard BioTools' technologies?
Who are the key customers of Standard BioTools?
How does Standard BioTools ensure quality and repeatability in its platforms?
